Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury
NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases
About This Grant
PROJECT SUMMARY/ABSTRACT The demand for liver transplantation far exceeds the number of suitable donor organs. Despite the organ shortage, due to increased risk for ischemia reperfusion injury (IRI), many marginal donor livers with steatosis go unused. While some IRI is unavoidable in all liver operations, in the setting of liver transplantation this can lead to primary non-function or early allograft dysfunction. The increasing prevalence of obesity associated metabolic dysfunction-associated steatotic liver disease increases the demand for liver transplant while also reducing the number of suitable donor livers. To address this shortfall, we must attenuate IRI in steatotic livers. However, there are no pharmacological interventions available to achieve this goal. Development of novel therapeutics is costly and time intensive. A practical alternative is to repurpose FDA approved drugs in clinical use. Fomepizole is an appealing candidate; it is used for the treatment of ethylene glycol poisoning, and recent studies have found fomepizole to be protective against acetaminophen (APAP) hepatotoxicity. Given similarities between APAP hepatoxicity and IRI, we will test the hypothesis that fomepizole protects against IRI by modulation of lipid metabolites and determine if the same mechanisms apply in steatotic livers. While there are no pharmacological agents available to reduce IRI, the use of machine perfusion (MP) procurement (as opposed to traditional static cold storage) has gained traction in the past decade and enabled the use of marginal donor livers by reducing IRI complications. However, many donor livers still do not pass viability testing with MP and are ultimately discarded. The use of adjunctive therapies may provide additional benefits over standard MP in reducing IRI, thus further expanding the use of marginal donor livers. Hence, testing therapeutics in the setting of MP, represents a novel way to address the donor shortage. In this proposal, we will investigate if fomepizole provides additional benefit in normothermic machine perfusion using an isolated perfused rat liver model. In alignment with the R03 funding mechanism, this proposal is a logical extension of my K08 proposal and provides a clear path toward an R01. The primary goals of this proposal are to delineate the mechanisms by which fomepizole reduces liver IRI and establish collaborations and innovative platforms to test therapeutics within the evolving landscape of liver preservation. At completion, I expect to provide support for repurposing fomepizole as a primary or adjunctive therapy to salvage marginal grafts, thus enabling safe, expanded use of donor grafts to decrease waitlist mortality and improve patient outcomes.
Grant Summary
Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury is a NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases grant providing up to $117K for university, nonprofit, healthcare org. Applications are due 2028-01-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $117K
2028-01-31
- 1Confirm your organization is eligible for Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury: Frequently Asked Questions
Who is eligible for the Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury?
Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury is offered by NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury provide?
Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury provides up to $117K per award from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury deadline?
Applications for Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury are due 2028-01-31 (open). Because deadlines can change, verify the date with the funder, NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury?
To apply for Novel Use of Fomepizole in Hepatic Ischemia Reperfusion Injury, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases.